Actinium Pharmaceuticals, Inc.
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Actinium Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to the advancement and commercialization of precision oncology treatments, including those for bone marrow transplantation, cell and gene therapies, and various adoptive cell approaches. Its leading therapeutic candidate, Iomab-B (I-131 apamistamab), an induction and conditioning agent for transplant, demonstrated positive primary endpoint results in the pivotal Phase 3 SIERRA trial for older patients with relapsed or refractory acute myeloid leukemia; however, the U.S. FDA has since requested further data demonstrating an overall survival benefit in an additional randomized clinical trial for Biologics License Application submission in the U.S.. Actinium is also advancing Actimab-A, a CD33-targeted therapeutic leveraging the alpha-emitter Actinium-225, positioned as a potential foundational therapy for acute myeloid leukemia and other myeloid conditions, with a pivotal Phase 2/3 study underway and additional research collaborations, including with Memorial Sloan Kettering Cancer Center, exploring novel combinations. The company's pipeline further encompasses ATNM-400, a first-in-class Actinium-225 radiotherapy targeting non-PSMA receptors for solid tumors like prostate, breast, and lung cancers, which has shown compelling preclinical efficacy. Other programs utilize diverse radioisotopes, such as Actinium-225 and Iodine-131, for targeted conditioning in cellular and gene therapies, exemplified by Iomab-ACT, and as standalone cancer treatments or in combination regimens. Actinium also distinguishes itself with proprietary cyclotron-based manufacturing technology for Actinium-225, aiming to establish a scalable and cost-effective supply of this critical isotope. Strategic alliances include a licensing agreement with Immedica Pharma AB for Iomab-B commercialization in Europe, the Middle East, and North Africa. Incorporated in 2000, the company maintains its headquarters in New York, New York.
Company News
Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer
Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models
Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026
Actinium Pharmaceuticals Announces Inducement Grants to New Employees
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models
Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development
Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Actinium Pharmaceuticals (NYSE:ATNM)
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. Actinium Pharmaceuticals (NYSE:ATNM) Financial Contrast
Palatin Technologies (OTCMKTS:PTNT) and Actinium Pharmaceuticals (NYSE:ATNM) Head to Head Review
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
NorthStar and QSA Global Announce Multi-Year Strategic Partnership to Strengthen Actinium-225 Supply Chain for Targeted Alpha Therapies